zoledronic acid has been researched along with Hyperparathyroidism in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Fardeen, KM; Kotecha, J; Mirzazadeh, M | 1 |
| Bae, WK; Chung, IJ | 1 |
| Sayin, M; Yazici, G | 1 |
| Asuncion, F; Chiusaroli, R; Khatri, R; Kostenuik, P; Ohishi, M; Ominsky, M; Schipani, E; Thomas, C | 1 |
| Chen, J; Li, N; Ling, R; Lv, Y; Wang, H; Wang, L; Wang, T; Yao, Q; Yi, J; Yuan, S; Zhang, J | 1 |
| Anastasilakis, AD; Polyzos, SA; Terpos, E | 1 |
| Civantos Modino, S; Díaz Guardiola, P; Guijarro de Armas, MG; Montaño Martínez, JM; Pavón de Paz, I; Zubieta Tabernero, J | 1 |
| Barone, A; Foppiani, L; Palummeri, E; Prete, C; Senesi, B; Trasciatti, S; Veneziano, M | 1 |
1 review(s) available for zoledronic acid and Hyperparathyroidism
| Article | Year |
|---|---|
Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman.
Topics: Aged; Aged, 80 and over; Bone Diseases, Metabolic; Cognition Disorders; Diphosphonates; Disease Progression; Diuretics; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Nervous System Diseases; Sodium Chloride; Treatment Outcome; Zoledronic Acid | 2005 |
7 other study(ies) available for zoledronic acid and Hyperparathyroidism
| Article | Year |
|---|---|
Hyperparathyroidism Following Denosumab and Zoledronate Therapy in a Secondary Care Setting.
Topics: Bone Density; Bone Density Conservation Agents; Denosumab; Humans; Hyperparathyroidism; Secondary Care; Zoledronic Acid | 2023 |
Full-blown hyperparathyroidism.
Topics: Adult; Biomarkers; Bone Density Conservation Agents; Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism; Infusions, Intravenous; Male; Parathyroid Hormone; Saline Solution; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2018 |
Hyperparathyroidism secondary to zoledronic acid infusion: case report.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hyperparathyroidism; Imidazoles; Lymphoma; Middle Aged; Stomach Neoplasms; Zoledronic Acid | 2009 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Humans; Hyperparathyroidism; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Porosity; Primary Myelofibrosis; Receptor, Parathyroid Hormone, Type 1; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Zoledronic acid may be a treatment option for hyperparathyroidism.
Topics: Bone Density Conservation Agents; Diphosphonates; Hyperparathyroidism; Imidazoles; Models, Biological; Thyroid Gland; Zoledronic Acid | 2009 |
Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Hyperparathyroidism; Imidazoles; Infusions, Intravenous; Stomach Neoplasms; Zoledronic Acid | 2009 |
[Primary hyperparathyroidism in a patient with Paget's bone disease].
Topics: Adenoma; Aged; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Osteitis Deformans; Osteoporosis; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Radionuclide Imaging; Zoledronic Acid | 2010 |